Tag: Gmg

The landscape of myasthenia gravis (MG) treatment has evolved beyond traditional immunosuppressants to include advanced, targeted injectable therapies. These newer options, including both subcutaneous injections and intravenous infusions, target specific components of the immune system to manage symptoms more effectively and improve quality of life.

Overactive complement system activity is a primary driver of several rare autoimmune diseases. For individuals with these challenging conditions, understanding *why do you take Ultomiris* is crucial to managing symptoms, preventing organ damage, and improving quality of life. This long-acting medication specifically targets a key protein in this immune pathway to provide sustained disease control.

Without treatment from complement inhibitors, the 10-year survival rate for patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) is just 65% [1.3.3]. Eculizumab revolutionized treatment for this and other rare diseases. But **how does Eculizumab work** to achieve this?